Alternatives to Lysodren If You Can't Fill Your Prescription

Lysodren (mitotane) is the only FDA-approved medication for adrenocortical carcinoma (ACC). That means there is no true drug-to-drug substitute for it in the treatment of ACC. However, when patients face access delays — or when Lysodren's side effects are intolerable — oncologists and endocrinologists sometimes turn to other medications that can help manage symptoms or slow the disease. This guide explains those options, their limitations, and what to discuss with your doctor.

Important: Never switch or discontinue Lysodren without guidance from your oncologist or endocrinologist. The information below is for educational purposes and should not replace a conversation with your treatment team.

Why There's No Perfect Replacement for Lysodren

Mitotane is the only drug that has earned FDA approval specifically for adrenocortical carcinoma — and clinical guidelines worldwide recognize it as the cornerstone of ACC medical therapy. Its dual role makes it especially hard to replace: it acts as an adrenal cytotoxin (attacking the tumor cells themselves) and a steroidogenesis inhibitor (reducing excess hormone production). No other drug does both of these things simultaneously.

That said, the alternatives below are sometimes used alongside mitotane or as temporary bridging therapy while access issues are resolved.

Ketoconazole (Off-Label)

Ketoconazole is an antifungal medication that, at higher doses, also inhibits steroid synthesis in the adrenal cortex. It is used off-label to manage hypercortisolism (excess cortisol) in patients with Cushing's syndrome and is sometimes combined with mitotane in ACC patients who need rapid cortisol control.

Advantages: Ketoconazole has a much faster onset of action than mitotane. Where mitotane can take 3 to 5 months to reach therapeutic plasma levels, ketoconazole can reduce cortisol within days. Doses typically range from 200 to 1,200 mg/day. It is widely available at retail pharmacies and is far less expensive than Lysodren.

Limitations: Ketoconazole has significant hepatotoxicity risk. Liver enzymes must be monitored closely, and it should not be started if liver function tests are more than three times the upper limit of normal. It is also a strong CYP3A4 inhibitor — the opposite of mitotane, which is a CYP3A4 inducer. This creates a complex drug interaction to manage when both are used together.

Metyrapone (Metopirone) — Off-Label

Metyrapone inhibits 11-beta-hydroxylase, an enzyme required for cortisol synthesis. It is sometimes used in combination with mitotane and ketoconazole in severe cases of hypercortisolism, or as a bridging agent during mitotane titration. Metyrapone has a short half-life and typically requires 4 doses per day.

Advantages: Quick onset; can be used alongside mitotane; not metabolized by CYP3A4 in a way that significantly interferes with mitotane levels. Limitations: Can cause hypertension, hypokalemia, hirsutism, and acne (due to buildup of androgen precursors). Less preferred for women with androgen-secreting ACC. Not FDA-approved specifically for Cushing's syndrome in the U.S.

Osilodrostat (Isturisa) — For Cushing's Disease

Osilodrostat is a newer steroidogenesis inhibitor that is FDA-approved for Cushing's disease (pituitary-driven excess ACTH). It inhibits 11-beta-hydroxylase and aldosterone synthase with a rapid onset of action and relatively limited drug interactions compared to ketoconazole.

Osilodrostat has been explored in ACC-related Cushing's syndrome and is seen as a useful option in cases where metyrapone is contraindicated. It does not, however, have the cytotoxic (tumor-killing) effect of mitotane — making it a steroid control agent rather than a cancer treatment in its own right.

EDP Chemotherapy (Etoposide, Doxorubicin, Cisplatin + Mitotane)

For patients with advanced or metastatic ACC, the standard first-line systemic treatment is the EDP-M regimen: etoposide, doxorubicin, and cisplatin combined with mitotane. This regimen was established by the FIRM-ACT trial, the largest randomized trial conducted in ACC.

If Lysodren is temporarily unavailable, the chemotherapy components (EDP) may continue under the guidance of your oncologist while the mitotane component is sourced. This requires close medical supervision.

Mifepristone (Korlym) — For Cushing's Syndrome Specifically

Mifepristone (brand name Korlym) is an FDA-approved treatment for hyperglycemia in adults with Cushing's syndrome who have type 2 diabetes or glucose intolerance and are not surgical candidates. Unlike the other agents listed here, it works as a glucocorticoid receptor antagonist — it doesn't lower cortisol levels, but blocks the receptor so the cortisol cannot act on tissues.

Mifepristone is a strong CYP3A4 inhibitor, which creates a complex pharmacokinetic interaction with mitotane (a CYP3A4 inducer). The two drugs are sometimes used together in specialist centers, but require careful management.

Having Trouble Finding Lysodren? medfinder Can Help

If you're exploring alternatives because you can't find Lysodren, the first step should be making sure you've exhausted the access options for Lysodren itself. medfinder is a paid service that calls pharmacies near you to find which ones can fill your prescription — saving you hours of frustrating calls. Before switching treatments, it's worth confirming that your Lysodren actually can't be filled.

See our companion guide: How to Find Lysodren In Stock Near You (Tools + Tips).